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Among the hallmarks of cancer are defective cell–cell and cell–matrix adhesion. Alterations in cadherin–catenin complexes
likely have a major contributing role in cell-adhesion defects in carcinomas arising in many different tissues. E-cadherin, the
prototypic member of the cadherin transmembrane protein family, regulates cell adhesion by interacting with E-cadherin
molecules on opposing cell surfaces. E-cadherin’s function in cell adhesion is also critically dependent on its ability to interact
through its cytoplasmic domain with catenin proteins. A diverse collection of defects alter cadherin–catenin function in cancer
cells, including loss-of-function mutations and defects in the expression of E-cadherin and certain catenins, such as -catenin.
Although there is much evidence that -catenin is deregulated in cancer as a result of inactivating mutations in the APC and
AXIN tumor-suppressor proteins and gain-of-function mutations in -catenin itself, the principal consequences of -catenin
deregulation in cancer appear to be largely distinct from the effects attributable to inactivation of E-cadherin or -catenin. In
this review, we highlight some of the specific genetic and epigenetic defects responsible for altered cadherin and catenin
function in cancer, as well as potential contributions of cadherin–catenin alterations to the cancer process.
© 2002 Wiley-Liss, Inc.
INTRODUCTION
The cadherins were first identified as a family of
single-pass transmembrane glycoproteins mediat-
ing calcium-dependent cell–cell adhesion, and it is
now well recognized that they play essential roles
in development, cell polarity, and tissue morphol-
ogy (Takeichi, 1991). E-cadherin is arguably the
prototypic member of the classical cadherin family,
and it plays a critical role in epithelial cell–cell
adhesion. Like the other members of the type I
classical cadherin family, E-cadherin has an extra-
cellular domain consisting of five cadherin-type
repeats that interact in a calcium-dependent fash-
ion with cadherin molecules on neighboring cells,
forming essentially a “molecular zipper” (Nagar et
al., 1996). E-cadherin’s cytoplasmic domain is
linked to the actin cytoskeleton through critical
interactions with catenins. The cadherin–catenin
complex is characteristically present in the adher-
ens junction between adjacent cells in normal ep-
ithelium (Fig. 1). Disruption of the cadherin–cate-
nin complex has been demonstrated in carcinomas
arising in many tissues and has been correlated
with various pathologic and clinical features, such
as tumor dedifferentiation, infiltrative growth,
lymph node metastasis, and a poorer patient prog-
nosis. The long-standing observation that tumor
cells demonstrate decreased cellular adhesion, as
well as the observation that E-cadherin expression
is frequently lost in human cancers, led investiga-
tors to hypothesize that changes in the cadherin–
catenin complex may play a causative role in cancer
development and progression. A considerable body
of data now firmly supports this view. This review
focuses on the different mechanisms by which cad-
herins and catenins are altered in human cancer
and the distinctive functional consequences of the
alterations observed.
CADHERIN ALTERATIONS IN CANCER
Germline CDH1 Mutations
Perhaps the strongest evidence in support of a
causal role for cadherin alterations in cancer patho-
genesis is the observation that germline mutations
in the gene encoding E-cadherin (Table 1) (known
as CDH1) strongly predispose affected individuals
to diffuse-type gastric cancer (Gayther et al., 1998;
Guilford et al., 1998, 1999; Keller et al., 1999;
Richards et al., 1999). In some kindreds segregat-
ing a germline CDH1 mutation, individuals have
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been identified with colorectal (Guilford et al.,
1998; Richards et al., 1999), breast (Guilford et al.,
1999; Keller et al., 1999), and prostate (Gayther et
al., 1998) cancers. However, the elevated risk of
these carcinomas in individuals who carry germline
CDH1 mutations is less certain than the markedly
elevated risk of gastric cancer. A causal role for
E-cadherin inactivation in cancer has been sup-
ported further by data showing that, in a mouse
model of pancreatic -cell cancer development,
E-cadherin inactivation is a rate-limiting step in the
progression from adenoma to carcinoma (Li et al.,
1998).
Somatic CDH1 Mutations
Somatic CDH1 gene mutations resulting in E-
cadherin inactivation have also been demonstrated
in carcinomas (Table 1). The highest mutation
frequencies appear to be in diffuse-type gastric and
infiltrative lobular breast carcinomas, with CDH1
mutations detected in nearly 50% of each tumor
type in some studies (Becker et al., 1994; Berx et
al., 1996, 1998). The original suggestion was that
CDH1 mutations in breast carcinoma were re-
stricted to tumors of lobular type, although CDH1
mutations also appear to be present in some inva-
sive ductal carcinomas (van de Wetering et al.,
2001). Somatic mutations in CDH1 have been dem-
onstrated in subsets of other malignancies, such as
endometrial and ovarian carcinomas (Risinger et
al., 1994) and signet-ring cell carcinomas of the
stomach (Muta et al., 1996). Somatic mutation in
one CDH1 allele has been shown to occur in com-
bination with inactivation of the other allele (Berx
et al., 1998). Thus, CDH1 inactivation seems to
adhere to the two-hit (biallelic) model for tumor-
suppressor gene inactivation (Comings, 1973;
Knudson, 1985).
Epigenetic Mechanisms Resulting in Cadherin Loss
Immunohistochemical studies have demon-
strated that loss of E-cadherin expression is a fre-
quent event in many types of carcinomas (Jiang,
1996; Papadavid and Katsambas, 2001). Yet, in
many cancer types where expression is frequently
lost, CDH1 mutations are rare or absent (Hirohashi,
1998). Proposed epigenetic mechanisms for E-cad-
herin loss include alterations in the expression
and/or function of the trans-acting factors that reg-
ulate CDH1 gene transcription, hypermethylation
of the CDH1 promoter, and chromatin-mediated
effects.
Studies on prostate and breast carcinoma cell
lines lacking identifiable mutations in the CDH1
gene suggest that, in some cases, transcriptional
mechanisms underlie loss of E-cadherin expres-
sion. In particular, CDH1 promoter-driven reporter
gene constructs are active in cells with detectable
Figure 1. The cadherin–catenin cell adhesion complex. E-cadherin
forms intercellular, calcium-dependent, homotypic interactions. The
cytoplasmic tail of E-cadherin interacts in a mutually exclusive manner
with either -catenin or -catenin (also called plakoglobin). - and
-catenin link E-cadherin to -catenin, and -catenin can bind to the
actin cytoskeleton either directly or indirectly through a number of
actin-associated proteins, including -actinin and vinculin. Additional
proteins, such as p120ctn (also called -catenin), bind to the more
membrane-proximal portion of the E-cadherin cytoplasmic domain.
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E-cadherin protein, but not in those cells that lack
E-cadherin expression (Bussemakers et al., 1994; Ji
et al., 1997). Analysis of breast cancer somatic cell
hybrids suggests that a dominant repression path-
way extinguishes CDH1 transcription through its
proximal promoter (Hajra et al., 1999), and E-box
elements within this region have been proposed to
be critical in the silencing of CDH1 transcription in
cancer (Giroldi et al., 1997). A number of transcrip-
tion factors may bind to CDH1 E-box elements to
repress transcription, including the zinc-finger tran-
scription factors Snail (Batlle et al., 2000; Cano et
al., 2000), SLUG (Hajra et al., 2002), EF1/ZEB-1
(Grooteclaes and Frisch, 2000), and SIP1/ZEB-2
(Comijn et al., 2001), and the basic helix–loop–
helix factor E12/E47 (Perez-Moreno et al., 2001).
Increased expression of Snail has been correlated
with loss of E-cadherin expression in various cancer
cell lines, including those derived from human
bladder, pancreas, colon, and breast carcinomas
(Batlle et al., 2000), oral squamous cell carcinomas
(Yokoyama et al., 2001), and melanomas (Poser et
al., 2001).
Hypermethylation of the CDH1 promoter has
been postulated to play a critical role in the loss of
E-cadherin expression observed in some primary
tumors and cell lines without identified CDH1 mu-
tations. CDH1 promoter hypermethylation has
been reported in breast, prostate, thyroid, gastric,
and other cancers (Graff et al., 1995, 1998; Yoshiura
et al., 1995; Tamura et al., 2000). The finding that
treatment of cell lines with demethylating agents
can, in some cases, restore E-cadherin expression
suggests that in some tumors, promoter hyper-
methylation plays an important role in silencing of
CDH1 expression. CDH1 promoter hypermethyl-
ation has also been reported as a mechanism of
inactivating the remaining wild-type CDH1 allele
in gastric carcinomas arising in individuals carrying
germline CDH1 mutations. It is worth noting that
the correlation between CDH1 promoter hyper-
methylation and loss of CDH1 transcripts and E-
TABLE 1. Adhesive Protein Gene Alterations in Human Cancers*
Gene Protein Alterationa Mechanism Tumor type (mutation frequencyb)
CDH1 E-cadherin Inactivation Germline gene mutation Diffuse-type gastric, colorectal, breast,
prostate
Somatic gene mutation Diffuse-type gastric (50%), lobular
breast (50%), invasive ductal breast,
endometrial, ovarian, signet-ring cell
type gastric
Epigenetic Breast, prostate, thyroid, gastric
CTNNA1 -catenin Inactivation Gene mutationc Cell lines only: lung, prostate, ovarian,
colon
CTNNB1 -catenin Activation Gene mutation Endometrial (45%), hepatocellular
(25%), endometrioid type ovarian
(25%), anaplastic thyroid (65%),
colorectal, squamous cell, prostate,
pancreatic, melanoma,
hepatoblastoma (50%), desmoid
tumor (50%), pilomatricoma (75%),
medulloblastoma
Other Wnt pathway defect:
APC mutation




Other Wnt pathway defect:
AXIN1 or AXIN2
mutation
Hepatocellular (5%), colorectal, ovarian
Inactivation Gene mutationc Cell lines only: signet-ring cell type
gastric
JUP -catenin Activation Gene mutationc Cell lines only: gastric
Inactivation ND
CTNND1 p120ctn Inactivation ND
*ND, not determined.
aFor all proteins, loss of expression has also been documented by immunohistochemical analysis of primary tumors.
bMutations rare except when frequency noted.
cDemonstrated only in cancer cell lines.
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cadherin protein is not exact in gastric carcinomas
and perhaps other tumors (Fearon, 2000; Tamura
et al., 2000). Additionally, some studies have been
unable to demonstrate that demethylating agents
can restore E-cadherin expression (Ji et al., 1997;
Hajra et al., 1999). Thus, promoter hypermethyl-
ation may be unrelated to CDH1 silencing in cer-
tain tissues and may have variable effects on CDH1
silencing in other settings.
Mechanisms other than repression by certain
transcription factors and promoter hypermethyl-
ation have been suggested to inactivate CDH1 ex-
pression in cancer. In particular, chromatin conden-
sation has been proposed to play a role in the
silencing of CDH1 expression in carcinomas (Hen-
nig et al., 1995). The various proposed mechanisms
of CDH1 silencing in cancer may not be mutually
exclusive. For instance, CDH1 promoter hyper-
methylation and chromatin remodeling may occur
in concert with or as a specific consequence of the
transcriptional repression effects of distinct trans-
acting transcription factors targeted to the CDH1
promoter. In support of this proposal, a strong pos-
itive association between CDH1 promoter hyper-
methylation and increased Snail expression has
been shown in some invasive ductal breast carci-
nomas (Cheng et al., 2001). The relative contribu-
tion and importance of specific transcription fac-
tors, promoter hypermethylation, and chromatin
condensation in the silencing of CDH1 expression
in carcinomas remains to be clarified further, al-
though overall the current data suggest that these
processes together result in CDH1 silencing.
Cadherin Switching
Notwithstanding the expansive body of data on
E-cadherin loss in cancer, there are data suggesting
that the inappropriate expression of nonepithelial
cadherins, such as N-cadherin and cadherin-11, ei-
ther in collaboration with or even instead of E-
cadherin loss, may play an important role in the
invasive and metastatic phenotype of cancer cells.
Concomitant upregulation of N-cadherin and/or
cadherin-11 and downregulation of E-cadherin has
been termed cadherin switching. Cadherin switching
has been demonstrated in primary tumors, includ-
ing prostate carcinomas and gastric signet-ring cell
carcinomas (Shibata et al., 1996a; Tomita et al.,
2000), as well as in several carcinoma-derived cell
lines (Islam et al., 1996; Giroldi et al., 1999; Pish-
vaian et al., 1999; Bussemakers et al., 2000). In
squamous cell carcinoma lines, N-cadherin expres-
sion appears to repress E-cadherin expression, and
cadherin switching from E- to N-cadherin is re-
sponsible for a change in cellular phenotype from
epithelial to scattered fibroblastic (Islam et al.,
1996). Endogenous N-cadherin expression in
breast cancer cell lines has been correlated with
increased cellular motility and invasion, and ex-
pression of exogenous E-cadherin in one such N-
cadherin–expressing line was unable to suppress
the motile and invasive properties of the cells
(Nieman et al., 1999). Additionally, expression of
N-cadherin was found to increase invasion and
motility in two different E-cadherin–expressing
cancer cell lines (Nieman et al., 1999; Hazan et al.,
2000).
CATENIN INACTIVATION IN CANCER
Catenin Gene Mutation
Inactivating mutations in CTNNA1, the gene en-
coding -catenin, have been demonstrated in some
lung, prostate, ovarian, and colon cancer cell lines
that lack normal cadherin-dependent cell–cell ad-
hesion (Table 1) (Shimoyama et al., 1992; Breen et
al., 1993; Morton et al., 1993; Oda et al., 1993;
Bullions et al., 1997; Roe et al., 1998; Vermeulen et
al., 1999). Additionally, immunohistochemical anal-
ysis has demonstrated loss of -catenin in some
primary tumors (Jiang, 1996; Papadavid and Kat-
sambas, 2001). In selected cell lines with absent or
defective -catenin protein, introduction of wild-
type -catenin restores cell–cell adhesion, retards
cell growth, and reduces tumorigenic growth in
nude mice (Watabe et al., 1994; Ewing et al., 1995;
Bullions et al., 1997). Thus, loss of -catenin likely
accounts for the absence of calcium-dependent
cell–cell adhesion in some cancers with intact E-
cadherin expression, and -catenin can reasonably
be considered an invasion suppressor molecule like
E-cadherin.
Although some immunohistochemical studies on
catenin expression in primary tumors have shown
loss of -catenin, -catenin, or p120ctn (Aberle et
al., 1995; Nakanishi et al., 1997; Dillon et al., 1998;
Papadavid and Katsambas, 2001), inactivating mu-
tations in the genes encoding these catenins have
been reported only rarely (Table 1). A human sig-
net-ring gastric cancer cell line has a homozygous
deletion in the -catenin gene CTNNB1, which
results in impaired cell–cell adhesion; normal cell
adhesion function could be restored in this line
after introduction of full-length -catenin (Oyama
et al., 1994; Kawanishi et al., 1995). In SV40-trans-
formed 3T3 cells lacking -catenin expression, re-
introduction of -catenin was found to suppress
tumorigenicity (Simcha et al., 1996). The overall
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paucity of inactivating alterations in -catenin and
-catenin could be attributable to the possibility
that the two proteins have largely redundant func-
tions in linking E-cadherin to -catenin in many
epithelial cell types. Hence, the loss of one of the
proteins would be insufficient to disrupt cell–cell
adhesion. Moreover, as reviewed below, the infre-
quent inactivation of -catenin and possibly also
-catenin in cancer cells may also be related to
their positive roles in Wnt signaling or other
growth-regulatory pathways.
Post-Transcriptional Effects on Catenin Function
The cadherin– catenin adhesion complex is
regulated by post-translational mechanisms, and
perturbations of this regulation may be important
in some human cancers. Tyrosine phosphoryla-
tion of catenins has been shown to decrease
cell– cell adhesiveness, whereas dephosphoryla-
tion appears to increase adhesion (Hirohashi,
1998). -Catenin, -catenin, and p120ctn all
demonstrate tyrosine phosphorylation by cyto-
plasmic protein kinases of the Src family and by
transmembrane receptor tyrosine kinases
(RTKs). Expression of the v-Src oncogene leads
to tyrosine phosphorylation of -catenin and re-
sults in decreased cadherin-mediated adhesion,
epithelial dedifferentiation, and increased cellu-
lar invasion (Matsuyoshi et al., 1992; Behrens et
al., 1993). Although there is a strong correlation
between -catenin tyrosine phosphorylation and
disruption of cadherin– catenin cell– cell adhe-
sion, it is not clear whether the tyrosine phos-
phorylation of -catenin is required for v-Src–
mediated disruption of adhesion (Takeda et al.,
1995). Evidence in favor of an important role for
Src family phosphorylation of catenins in trans-
formation comes from mutational studies of the
Src protein p60, which demonstrated that
p120ctn and -catenin are phosphorylated only
by kinase-active, transformation-capable p60,
and not by transformation-defective p60 (Reyn-
olds et al., 1989; Hamaguchi et al., 1993). At
present, although the correlations observed are
suggestive, it remains uncertain whether onco-
genic alterations in cytoplasmic protein kinases
directly perturb cell– cell adhesion mediated by
the cadherin– catenin complex.
Similar to cytoplasmic tyrosine kinases, RTKs
may also disrupt cellular adhesion by phosphoryla-
tion of catenins. Both hepatocyte growth factor/
scatter factor and epidermal growth factor (EGF)
induce phosphorylation of -catenin and -catenin
in human carcinoma cell lines (Shibamoto et al.,
1994). EGF, platelet-derived growth factor, and
colony-stimulating factor all stimulate tyrosine
phosphorylation of p120ctn (Downing and Rey-
nolds, 1991; Kanner et al., 1991). Two RTKs that
are overexpressed in human carcinomas, EGF re-
ceptor and ERBB2 (HER2/NEU), have been
shown to interact directly with -catenin (Hos-
chuetzky et al., 1994; Ochiai et al., 1994; Kanai et
al., 1995). In carcinoma cell lines, EGF treatment
causes catenin phosphorylation, alterations in the
subcellular localization of cadherin, and disruption
of the cadherin–catenin linkage to the actin cy-
toskeleton (Shiozaki et al., 1995; Hazan and Nor-
ton, 1998). A deleted form of -catenin, which
binds to ERBB2 but not to E-cadherin, was shown
to act in a dominant-negative manner to prevent
ERBB2’s interaction with endogenous -catenin
and to inhibit cancer cell invasion and metastasis
(Shibata et al., 1996b), consistent with the notion
that ERBB2 modulates cadherin–catenin-medi-
ated adhesion in vivo.
In addition to the potential role of kinases in
post-transcriptional regulation of the cadherin–
catenin complex, GTPases also appear to play a
possible role in regulating cadherin– catenin
function. Studies indicate that Rho-family small
GTPases, including proteins Rho, Rac, and
Cdc42, function in cadherin-mediated cell– cell
adhesion. These GTPases cycle between an in-
active, GDP-bound form and an active, GTP-
bound form. Rho and Rac are required for the
formation of cadherin-based cell– cell adhesion
contacts (Braga et al., 1997; Takaishi et al., 1997).
A recent report offers some insight into how Rho
may be mechanistically linked to the functioning
of the cadherin– catenin complex. Specifically,
p120ctn was shown to bind cadherins and RhoA
in a mutually exclusive manner, binding to inac-
tive RhoA and retaining it in an inactive state
(Anastasiadis et al., 2000), thus inhibiting down-
stream signaling believed to promote strong ad-
hesion. p120ctn binding to cadherins also
strengthens cellular adhesion; thus, a shift from
p120ctn-cadherin binding to p120ctn-RhoA
binding could perhaps decrease cadherin– cate-
nin-mediated adhesion by multiple mechanisms.
Rho-family GTPases Cdc42 and Rac1 also di-
rectly regulate E-cadherin activity (Fig. 2) (Kaibu-
chi et al., 1999). When Cdc42 and Rac1 are in the
inactive form, their effector protein, IQGAP1,
binds both to the cytoplasmic domain of E-cad-
herin and to -catenin, apparently causing dissoci-
ation of -catenin from the cadherin–catenin com-
plex and a decrease in cell adhesion (Kuroda et al.,
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1998; Fukata et al., 1999). In contrast, when Cdc42
and Rac1 are in the active form, they interact with
IQGAP1, thus preventing it from interacting with
-catenin, and the cadherin–catenin complex is
stabilized. In the case of the exchange factor
Tiam-1, by stimulating the formation of active
Rac1, Tiam-1 is likely to increase E-cadherin–me-
diated cell–cell adhesion. This may possibly ex-
plain Tiam-1’s previously identified ability to in-
hibit invasion of epithelial cells (Hordijk et al.,
1997). This pathway may be important in a consid-
erable fraction of human cancers, given that onco-
genic Ras has been shown to downregulate both
Rac1 and Tiam-1 and to induce an epithelial-to-
mesenchymal transition in cell phenotype (Zondag
et al., 2000).
ACTIVATION OF CATENINS IN CANCER
The Wnt Signaling Pathway
In addition to its well-defined role in cellular
adhesion, -catenin functions in the Wnt signaling
pathway (Fig. 3) (Polakis, 2000). Consistent with
its ostensibly independent functions in cell adhe-
sion and signal transduction, at least two distinct
pools of -catenin exist in cells, a cadherin-associ-
ated (cell membrane–associated) pool and a pool
involved in Wnt signaling and gene transcription.
The -catenin pool that functions in Wnt signaling
and gene transcription is regulated in part by the
adenomatous polyposis coli (APC) tumor-suppres-
sor protein, AXIN proteins, and glycogen synthase
kinase 3 (GSK3) (Polakis, 2000). In the absence
Figure 2. GTPase/IQGAP effects on the cadherin–catenin adhesion
complex. When Cdc42 and Rac1 are in the active form, they interact
with their effector protein IQGAP1 to sequester it from the cadherin–
catenin adhesion complex, resulting in complex stabilization. When the
GTPases are in the inactive form, IQGAP1 binds both to the cytoplas-
mic domain of E-cadherin and to -catenin, resulting in disruption of the
adhesion complex. Tiam-1 is a guanine nucleotide exchange factor that
stimulates the formation of active Rac1, thus stabilizing the cadherin–
catenin complex.
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of a Wnt signal, -catenin is bound by AXIN and
APC and phosphorylated by GSK3 at one or more
serine or threonine residues in its amino (N)-ter-
minal domain. The N-terminally phosphorylated
-catenin is then recognized and ubiquitinated by
a multiprotein complex that includes the F-box
protein -TrCP, with resultant degradation of the
ubiquitinated -catenin by the proteasome (Po-
lakis, 2001). Additionally, nonphosphorylated
-catenin can be degraded by the ubiquitin-protea-
some pathway, utilizing a unique protein complex
that includes the F-box protein Ebi rather than
-TrCP (Polakis, 2001). Wnt signals activate path-
ways that lead to inhibition of GSK3 activity and
sequestration of AXIN at the cell membrane by
LRP5/6, both of which contribute to the resultant
stabilization of -catenin (Nusse, 2001). The stabi-
lization of -catenin leads to its enhanced interac-
tion with members of the T-cell factor/lymphoid
enhancer factor (Tcf/Lef) family of transcription
factors (Behrens et al., 1996). -Catenin’s interac-
tion with Tcf/Lef proteins alters their transcrip-
tional activity, resulting, in many cases, in activa-
tion of genes with Tcf/Lef binding sites in their
regulatory regions.
Mutational Deregulation of Catenin Function
Deregulation of the Wnt pathway has been
shown to occur by several different mutational
mechanisms in human cancers (Table 1) (Polakis,
2000). Mutations in the CTNNB1 gene in the se-
quences encoding the critical serines and threo-
nines at -catenin’s N-terminus have been seen in
many cancer types, including melanoma, colorectal
carcinoma, hepatocellular carcinoma, medulloblas-
toma, hepatoblastoma, endometrial carcinoma,
squamous cell carcinoma of the head and neck,
prostate carcinoma, desmoid tumors, pilomatrico-
mas, pancreatic carcinoma, ovarian carcinoma, and
thyroid carcinoma (Morin, 1999; Polakis, 2000).
These mutations render the mutant -catenin pro-
teins resistant to phosphorylation by GSK3. In-
Figure 3. The canonical Wnt signaling pathway. A: -Catenin is
degraded in the absence of Wnt signals. In the absence of signals from
upstream factors, such as those attributed to Wnt interactions with the
Frizzled-LRP5/6 receptor complex, GSK3 forms a multiprotein com-
plex with the APC tumor suppressor, -catenin, and AXIN1 or AXIN2
(also called axil or conductin). GSK3 phosphorylates -catenin on
likely multiple serine and threonine residues in its N-terminal domain,
thus targeting -catenin for recognition by specific ubiquitination fac-
tors, including the F-box protein -TrCP, and subsequent degradation
by the proteasome. Nonphosphorylated -catenin may also be de-
graded by the ubiquitin-proteasome pathway, although, in this case, the
ubiquitination complex contains the F-box protein Ebi and other unique
factors. B: Wnt signals result in -catenin stabilization and the forma-
tion of -catenin–Tcf/Lef complexes. When Wnt signals through the
Frizzled-LRP5/6 receptor complex, dishevelled is activated and inhibits
the function of GSK3. Inhibition of GSK3 results in decreased phos-
phorylation of -catenin and subsequent -catenin stabilization. Addi-
tionally, Wnt signaling recruits AXIN to the cytoplasmic domain of
LRP5/6, which also contributes to the stabilization of -catenin. The
elevated levels of -catenin appear to lead to its increased complex
formation with members of the Tcf/Lef transcription factor family and
resultant effects on the transcription of -catenin–Tcf/Lef target genes.
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terestingly, it does not appear that cadherin–cate-
nin-mediated adhesion is adversely affected by the
oncogenic mutations in -catenin. Inactivating mu-
tations in the APC tumor-suppressor gene appear to
inhibit formation of the functional GSK3/APC/
AXIN/-catenin complex as well as interfere with
APC’s function in the export of -catenin from the
nucleus (Henderson, 2000; Rosin-Arbesfeld et al.,
2000). APC mutations have been found in roughly
70–80% of colorectal carcinomas and a subset of
other cancers, including gastric, pancreatic, hepa-
tocellular, breast, and ovarian carcinomas, medul-
loblastomas, desmoid tumors, and hepatoblastomas
(Polakis, 1995; Laurent-Puig et al., 1998). Similar
to APC mutations, inactivating mutations in AXIN1
or AXIN2 in cancer cells appear to stabilize -cate-
nin (Peifer and Polakis, 2000). Thus far, AXIN1 and
AXIN2 mutations have been seen in some hepato-
cellular (Satoh et al., 2000), colorectal (Liu et al.,
2000), and ovarian (Wu et al., 2001) carcinomas.
The presumed critical consequence of the acti-
vating mutations in -catenin or the inactivating
mutations in APC and AXIN is elevated levels of
-catenin in the cytoplasm and the nucleus. The
elevated levels of -catenin lead to the constitutive
formation of -catenin–Tcf/Lef complexes and al-
tered transcription of Tcf/Lef target genes. Pro-
posed Tcf/Lef-regulated target genes in cancer
cells include MYC (He et al., 1998), cyclin D1
(Shtutman et al., 1999; Tetsu and McCormick,
1999), matrix metalloproteinase 7 (MMP-7) (Brabletz
et al., 1999; Crawford et al., 1999), Tcf7 (Roose et
al., 1999), Lef-1 (Hovanes et al., 2001), peroxisome
proliferator-activated receptor delta (PPAR) (He et
al., 1999), and gastrin (Koh et al., 2000).
A number of lines of evidence indicate that
-catenin may also function in the Wnt signaling
pathway (Barker and Clevers, 2000; Zhurinsky et
al., 2000). To date, there have been no reports of
-catenin mutations in primary human tumors, al-
though a missense mutation at one of the con-
served serine residues in -catenin’s N-terminus
was found in a gastric cancer cell line that showed
deregulated Tcf/Lef transcriptional activity but no
mutations in -catenin (Caca et al., 1999). Al-
though conclusive data establishing that -catenin
functions as an oncogene in human cancer have yet
to be obtained, there are some additional data that
implicate deregulation of -catenin in cancer. First,
like -catenin, -catenin binds to the APC and
AXIN proteins (Hulsken et al., 1994; Shibata et al.,
1994; Rubinfeld et al., 1995; Kodama et al., 1999).
Second, akin to some of the effects seen on -cate-
nin levels and localization in cells with APC de-
fects, APC inactivation in colon cancer cells leads
to altered regulation of -catenin (Kolligs et al.,
2000). Third, upon its overexpression in the RK3E
in vitro model system, wild-type -catenin can pro-
mote neoplastic transformation (Kolligs et al.,
2000).
Interestingly, although mutations in -catenin’s
N-terminus are required to activate its oncogenic
potential and wild-type -catenin has no transform-
ing activity in the RK3E transformation model,
wild-type -catenin is transforming in RK3E, and
mutations in the conserved N-terminus of -cate-
nin do little to enhance its transforming activity
(Kolligs et al., 2000). This observation might offer
some clues to why mutations in -catenin are rare
in cancer. Further work will be needed to demon-
strate that -catenin plays an important role in
cancer, although, given most of the observations to
date, it might be interesting to determine whether
any tumors demonstrate genomic amplification of
-catenin as a mechanism for increased -catenin–
Tcf/Lef target gene activation. It is worth noting
that -catenin appears to have some effects on
Tcf/Lef transcriptional regulation distinct from
those seen with -catenin (Kolligs et al., 2000),
consistent with the notion that the functions of -
and -catenin are not equivalent in either signaling
or cell–cell adhesion. Deregulation of both pro-
teins may yield cooperative effects and may be
important in the genesis of certain cancers, such as




Role of Loss-of-Function Defects in E-Cadherin
and Catenin
In several cancer types, loss of either E-cadherin
or -catenin has been correlated with tumor de-
differentiation, infiltrative growth, lymph node me-
tastasis, and poorer patient prognosis. Additionally,
in in vitro models, loss of E-cadherin function in-
creases invasive growth, and reintroduction of
functional E-cadherin into cells with endogenous
E-cadherin defects suppresses their invasive be-
havior (Behrens et al., 1989; Vleminckx et al.,
1991). A simple model might be that the cadherin–
catenin complex has a purely mechanical function
by attaching neighboring cells to one another.
However, there is increasing evidence that the cad-
herin–catenin complex also functions in signaling.
Unfortunately, the signaling pathways and proteins
specifically modulated by cadherin-dependent ad-
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hesion are not yet well delineated, although a few
clues seem to have emerged. For example, with
respect to effects on gene expression, the E-cad-
herin binding protein p120ctn has been shown to
interact with the zinc-finger transcription finger
Kaiso (Daniel and Reynolds, 1999). Therefore, al-
terations in gene transcription after loss of E-cad-
herin may be mediated through Kaiso.
In addition, whereas tyrosine phosphorylation of
catenins is likely to play an important role in mod-
ulating cadherin–catenin complexes, defects in the
expression of E-cadherin or the catenins may lead,
in turn, to altered tyrosine kinase localization
and/or function, resulting in aberrant phosphoryla-
tion of various protein substrates. Because protein
tyrosine phosphatases have also been shown to
interact with the cadherin–catenin adhesion com-
plex (Brady-Kalnay et al., 1995; Balsamo et al.,
1996; Fuchs et al., 1996; Kypta et al., 1996), defects
in cadherin and/or catenin expression may alter the
function of tyrosine phosphatases and their sub-
strates as well. Nevertheless, whereas the possible
effects of cadherin–catenin inactivation on tyrosine
kinase and phosphatase function are of some inter-
est, vigorous approaches and thoughtful interpreta-
tion of the data will be critical to define the spec-
ificity of the effects on cancer cell phenotype
resulting directly from the alterations in cadherin–
catenin expression and function. Factors contribut-
ing to this view are the many and diverse cellular
functions of tyrosine kinases and phosphatases
(Pawson and Nash, 2000) and the possibility of
bidirectional interactions between these factors
and the cadherin–catenin complex. As such, it will
be critical to establish definitively that altered cad-
herin–catenin function has a contributory role in
modulating tyrosine phosphorylation and the can-
cer cell phenotype.
Although -catenin functions as a transcription
factor, inactivation of E-cadherin and the resultant
disruption of cellular adhesion do not appear to
result in significant increases in the levels of free
-catenin and increased transcription of Tcf/Lef
target genes. Introduction of E-cadherin into a cell
line lacking E-cadherin and demonstrating consti-
tutively active -catenin–Tcf/Lef signaling can
help sequester -catenin and reduce Tcf/Lef tran-
scription (Gottardi et al., 2001). However, the con-
verse is not true, given that loss of endogenous
E-cadherin expression does not result in constitu-
tive -catenin–Tcf/Lef transcriptional activation
(Caca et al., 1999; van de Wetering et al., 2001).
These latter observations suggest that a functional
-catenin phosphorylation and degradation path-
way is sufficient to remove excess -catenin from
the cytoplasm after loss of E-cadherin, thus pre-
venting potential oncogenic signaling.
Role of Cadherin Switching
Expression of nonepithelial cadherins or even
inappropriate expression of epithelial cadherins on
carcinoma cells, perhaps those characteristic of
other epithelial cell types or lineages, may facilitate
the invasive properties of the neoplastic cells
through novel homotypic interactions with cad-
herin molecules expressed by stromal cells and/or
heterologous epithelial cells. This has been a pro-
posed mechanism for cellular invasion by N-cad-
herin–expressing breast cancer cells (Hazan et al.,
1997) and for invasion by gastric carcinomas and
breast carcinomas with elevated cadherin-11 ex-
pression (Shibata et al., 1996a; Pishvaian et al.,
1999). Of note, it has been reported that the inap-
propriate expression of N-cadherin can increase
invasion into an extracellular matrix in the absence
of other cell types (Nieman et al., 1999), suggesting
a possible role for activation of other signaling path-
ways, perhaps including altered integrin function,
in the increased motility of N-cadherin–expressing
cells. Given the distinct roles of E-cadherin vs.
N-cadherin and cadherin-11 in homotypic adhesive
interactions between epithelial vs. nonepithelial
cells, respectively, both the loss of E-cadherin ex-
pression and the gain of N-cadherin or cadherin-11
expression are likely to be important in modulating
the adhesive properties of the carcinoma cells. If
specific transcription factors that facilitate cadherin
switching are identified, it will further support this
model and its importance.
Role of Gain-of-Function Alterations in the
Catenins
As reviewed above, activating mutations in the
gene encoding -catenin or inactivating mutations
in APC, AXIN1, or AXIN2 lead to the deregulation
of -catenin levels and localization and the consti-
tutive interaction of -catenin with Tcf/Lef tran-
scription factors. Several genes likely to be regu-
lated directly by the -catenin–Tcf/Lef complex
have been identified, and it is believed that a
number of them may play a critical role in aspects
of the cancer phenotype. As mentioned previously,
among the candidate genes are MYC (He et al.,
1998), cyclin D1 (Shtutman et al., 1999; Tetsu and
McCormick, 1999), matrix metalloproteinase 7
(MMP-7) (Brabletz et al., 1999; Crawford et al.,
1999), Tcf7 (Roose et al., 1999), Lef-1 (Hovanes et
al., 2001), peroxisome proliferator-activated receptor
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delta (PPAR) (He et al., 1999), and gastrin (Koh et
al., 2000). Some of these genes are discussed fur-
ther below.
Both MYC and cyclin D1 are well-characterized
oncogenes that are themselves frequently altered
in human carcinomas. Presumably, their roles in
cancers with defects in -catenin regulation
might be akin to the roles they play in other
cancer types, where they are affected by gain-of-
function mutations. These roles include the
well-defined effects of the c-Myc protein on the
transcription of genes involved in cell prolifera-
tion and cell growth and the effects of cyclin D1
on cell-cycle progression. The matrix metallopro-
teinases (MMPs) were first defined in large part
because of their roles as connective tissue–de-
grading enzymes produced by human tumors.
The MMPs function in basement-membrane and
connective-tissue destruction and may contrib-
ute to tumor progression, invasion, and metasta-
sis by this activity (MacDougall and Matrisian,
1995). MMPs may also have the ability to cleave
and inactivate transmembrane growth-inhibitory
proteins and/or secreted growth-inhibitory fac-
tors. In addition, MMPs may cleave and activate
different transmembrane, cell-associated, or se-
creted proteins that stimulate cell growth. All of
these functions could contribute to the invasive
and metastatic properties of tumor cells. MMP-7
appears to be upregulated in colon tumors at
both early and later stages of tumorigenesis (Wil-
son and Matrisian, 1996), and evidence of MMP-7
as a specific target of -catenin–Tcf/Lef tran-
scription (Brabletz et al., 1999; Crawford et al.,
1999) is supported by other findings. For exam-
ple, elevated MMP-7 expression has been ob-
served in almost all (88%) intestinal tumors aris-
ing in the APCMin mouse model for familial
adenomatous polyposis, in which there is an in-
activating germline mutation in one of the two
murine homologs of APC (Wilson et al., 1997).
Additionally, mice that carry the APCMin allele as
well as targeted deletions of both MMP-7 alleles
show a marked suppression of intestinal tumor
formation compared to the situation in APCMin
mice carrying wild-type MMP-7 alleles (Wilson et
al., 1997). Overall, the data strongly support the
notion that MMP-7 is a direct target of -catenin–
Tcf/Lef transcriptional activation and imply that
MMP-7 likely has important functions in tumors
arising as a result of -catenin deregulation.
The genes Tcf7 and Lef-1, encoding the Tcf1 and
Lef-1 protein products, respectively, are likely tar-
gets of -catenin signaling based on their potential
to function in cellular feedback loops. Interest-
ingly, each of these genes encodes multiple iso-
forms of the proteins, some of which can bind
-catenin and facilitate transcriptional activation of
Tcf/Lef-regulated target genes, and others that
cannot bind -catenin and thus act in a dominant-
negative fashion. In the case of Tcf7, these domi-
nant-negative isoforms that do not bind -catenin
are specifically upregulated by the -catenin–Tcf/
Lef complex, probably in an attempt to turn off
-catenin–Tcf/Lef signaling, given that the iso-
forms compete for Tcf/Lef DNA-binding sites in
the regulatory regions of target genes (Roose et al.,
1999). In contrast to the situation with the Tcf7
gene and dominant-negative Tcf1 isoform induc-
tion, Lef-1 isoforms that can bind -catenin appear
to be selectively upregulated by the -catenin–
Tcf/Lef transcription complex, thus resulting in a
positive feedback loop in which the oncogenic sig-
nal may, in fact, be amplified (Hovanes et al.,
2001). The specific contributions of the seemingly
competing effects of the activation of Tcf1 and
Lef-1 isoforms by -catenin–Tcf/Lef transcription
in normal and neoplastic tissues remain largely
undefined at present.
As discussed above, some evidence has been
obtained that defects in -catenin regulation may
also be a factor in cancer, such as in colon and
other cancers with APC or AXIN defects.
Whereas both - and -catenin appear to require
Tcf/Lef function for neoplastic transformation
and a number of target genes may be activated
similarly as a consequence of either - or -cate-
nin deregulation (Kolligs et al., 1999, 2000), some
differences appear to exist in their transcriptional
targets. Specifically, at least in some cell types,
-catenin may activate the MYC gene far more
potently than does -catenin (Kolligs et al.,
2000). The further characterization of both com-
mon and unique gene targets of the two proteins
should help to clarify the mechanisms by which
each contributes to cancer development.
SUMMARY AND FUTURE DIRECTIONS
Three distinctive consequences of alterations
in the cadherin– catenin complex arise from the
defects commonly seen in cancer cells. These
consequences are loss of adhesion complex func-
tion, most commonly attributed to inactivation of
E-cadherin or -catenin expression or function;
aberrant cadherin– catenin complex formation
and function arising from cadherin switching;
and altered cell signaling and target gene tran-
scription resulting from deregulation of -cate-
264 HAJRA AND FEARON
nin and also possibly -catenin after gain-of-
function defects in -catenin or loss-of-function
defects in APC or the AXINs. The role of cell-
signaling proteins that associate with the cadher-
in– catenin complex is an important area for fur-
ther study, particularly with respect to the
specific signaling alterations seen after disrup-
tion of the adhesion complex. The mechanism
and significance of cadherin switching also re-
quire further investigation. The finding that
chromosome arm 16q contains genes encoding
several classical cadherin-family members, in-
cluding E-cadherin, cadherin-11, P-cadherin, and
H-cadherin (Lee, 1996; Kremmidiotis et al.,
1998), presents the interesting question of
whether there is concerted regulation of these
genes in cadherin switching. Finally, it seems
likely that novel catenin–Tcf/Lef-regulated
genes will continue to be identified in the near
future, and thus the specific effects attributable
to -catenin vs. -catenin deregulation in cancer
will be better understood. There is no question
that changes in the cadherin– catenin complex
are important in carcinoma development and
progression. The hope is that further studies will
soon offer a fuller picture of the molecular details
and consequences of the alterations.
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